Keyword: Seattle Genetics
Both Seattle and Pieris have been busy on the deal front, and today their lists grew longer as the two pair on developing immuno-oncology treatments.
After a deal for Immunomedics fell through last May, Seattle Genetics has scaled down spending to ink a $614 million deal for Cascadian Therapeutics.
News that the Trump administration is axing the Obama-era Deferred Action for Childhood Arrivals program has been met with dismay by biotech leaders.
Seattle Genetics has called a halt to all clinical testing of vadastuximab talirine (SGN-CD33A) after seeing a higher rate of patient deaths with the drug in a phase 3 trial.
Debiopharm has bought a phase 2 antibody-drug conjugate (ADC) from ImmunoGen to add to its clinical-phase cancer pipeline.
Scott Gottlieb was confirmed to lead FDA, neuroscientist Thomas Insel left Verily, Immunomedics' CEO and CSO stepped down.
Seattle Genetics terminated a major drug tie-up with Immunomedics after intense legal battles, as Immunomedics axed CEO Cynthia Sullivan.
Embattled Immunomedics has some good news to report on its lead antibody-drug conjugate program, with a preliminary study showing IMMU-132 has activity in small cell lung cancer.
VenBio has criticized the timing and terms of Immunomedics’ licensing deal with Seattle Genetics.
Seattle Genetics is to pay $250 million upfront for the rights to Immunomedics’ solid tumor asset IMMU-132.